Galiximab
Galiximab is a monoclonal antibody designed for the treatment of B-cell lymphoma. As of September 2009, it is undergoing Phase III clinical trials.[1] The drug is a chimeric antibody from Macaca irus and Homo sapiens.[2]
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric (primate/human) |
| Target | CD80 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
  | |
References
- "Biogen Idec: Pipeline". Archived from the original on 2008-05-17. Retrieved 2009-09-24.
- WHO Drug Information
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.